30
Participants
Start Date
November 19, 2024
Primary Completion Date
October 31, 2029
Study Completion Date
October 31, 2029
Capmatinib
Patients will be administered capmatinib orally at a daily dose of 800 mg consisting of 400 mg (two 200mg tablets) twice daily. Each cycle of treatment will consist of 28 days and patients may continue on treatment until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent.
NOT_YET_RECRUITING
Belfast City Hospital, Belfast
RECRUITING
University Hospital Birmingham, Birmingham
RECRUITING
Bristol Haematology and Oncology Centre, Bristol
RECRUITING
Velindre Cancer Centre, Cardiff
RECRUITING
Western General Hospital, Edinburgh
RECRUITING
The Beatson Hospital, Glasgow
RECRUITING
Leicester Royal Infirmary, Leicester
RECRUITING
University College London Hospital, London
RECRUITING
Guy's Hospital, London
RECRUITING
The Christie Hospital, Manchester
RECRUITING
Clatterbridge Cancer Centre, Metropolitan Borough of Wirral
RECRUITING
Freeman Hospital, Newcastle
NOT_YET_RECRUITING
Churchill Hospital, Oxford
RECRUITING
Western Park Hospital, Sheffield
RECRUITING
Southampton General Hospital, Southampton
RECRUITING
Royal Marsden Hospital, Sutton
Lead Sponsor
Collaborators (1)
University of Birmingham
OTHER
Royal Marsden NHS Foundation Trust
OTHER
Novartis Pharmaceuticals
INDUSTRY
University of Manchester
OTHER
Cancer Research UK
OTHER